← Eichor
Study identifier: NCT07219849 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure

Condition: Seasonal Allergic Rhinitis (SAR)  ·  Sponsor: Alixer Nexgen Therapeutics Limited

PhasePhase 2
Planned participants164
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersYes

About this study

This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.

This description comes directly from the study's public registry record.

Talk to the study team

Akhilesh Sharma  ·  +912239829999  ·  akhilesh.sharma@alkem.com

Yogesh Rane  ·  +919820587254  ·  yogesh.rane@alkem.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cliantha ResearchMississauga, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07219849